drugset / Trial / NCT05661552
Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI
RandomizedParallel-groupOpen-labelTreatment
Summary
Investigators aimed to evaluate efficacy and safety of early Initiation of evolocumab and combination lipid-lowering agent (statin + Ezetimibe) on lipid profiles changes in patients with ACS undergoing PCI
Timeline
- Start
- 2022-12-01
- Primary completion
- 2025-02-05
- Completion
- 2025-02-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Evolocumab | Monoclonal antibody | 140 mg | Subcutaneous |
| Background | Ezetimibe | Unknown | 10 mg | — |
| Background | Rosuvastatin | Small molecule | 5 mg | — |